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Congenital rubella syndrome (CRS) is a rare but potentially debilitating disease with lifelong consequences. Although there is no cure, it is 
almost completely preventable by an effective immunisation programme. We present two confirmed cases of CRS diagnosed in the neonatal 
unit at Groote Schuur Hospital in 2011 and discuss aspects of the disease and its prevention.
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ARTICLE
The exact incidence of congenital rubella syndrome (CRS) is not 
known in South Africa, but it is estimated that approximately 
660 cases occur annually.1 Acquired and congenital rubella are not 
notifiable diseases in this country, and epidemics often go unnoticed. 
Although classically a triad of cataracts, deafness and cardiac disease, 
the clinical manifestations of CRS vary from mild and unrecognised 
to severely debilitating. Congenital rubella is completely preventable 
by having an effective immunisation programme in place. Currently 
routine rubella vaccination does not form part of the Expanded 
Programme for Immunization (EPI) in South Africa. The availability 
of the vaccine in the private sector may be setting our population up 
for a surge in new cases of CRS.
In 2011 there were 2 confirmed cases of congenital rubella in the 
Neonatal Unit at Groote Schuur Hospital, Cape Town.
Case reports
Case 1
A baby weighing 1 980 g and scored at 36 weeks’ gestation using 
the modified Ballard score2 was born to a 14-year-old mother who 
despite her young age had been pregnant previously and was well 
known to the social services. She had booked late but was HIV- 
and RPR-negative. She reported no viral illness or rash early in 
the pregnancy.
Because of the unexplained preterm labour and mild respiratory 
distress the baby was admitted to the neonatal nursery, a septic screen 
was done and first-line antibiotics were started. Of further concern 
on clinical examination was symmetrical growth restriction, the 
presence of leukocoria of the left eye and a systolic murmur. There 
was no associated rash or microcephaly. A blood sample was sent to 
screen for congenital infections including rubella.
On day 3 of life the baby was noted to be lethargic with a slightly full 
fontanelle. An ultrasound scan of the head showed no hydrocephalus 
or structural abnormalities. Septic markers were negative, but 
the antibiotics were continued. On day 4 the baby had an acute 
decompensation, requiring resuscitation, intubation and ventilation. 
Blood gas measurements showed marked metabolic acidosis 
with a raised lactate level. Multi-organ involvement manifested 
as renal impairment, raised liver transaminases and disseminated 
intravascular coagulation with thrombocytopenia. Repeat septic 
markers and culture remained negative. Formal echocardiography 
ruled out coarctation of the aorta, but diagnosed a large patent ductus 
arteriosus (PDA) with no evidence of cardiac failure. Continuous 
cerebral function monitoring (CFM) showed burst suppression on 
the trace. Despite full supportive care and review of the antibiotic 
cover, there was no neurological improvement after 96 hours and the 
CFM readings continued to show a background trace consistent with 
poor outcome. After consultation with the mother and grandmother, 
the decision was made to de-escalate therapy and the baby died 
12 hours after extubation. Serum rubella IgM and urine rubella 
polymerase chain reaction (PCR) confirmed the diagnosis of rubella, 
and cerebrospinal fluid PCR (sent postmortem) demonstrated that 
rubella meningo-encephalitis was present.
Case 2
A baby weighing 2 190 g was delivered at term via caesarean section 
for fetal distress. His mother was a 20-year-old primigravida who 
reported no rash or viral illness during her pregnancy but did have 
contact in the early months with a child who had a rash suggestive 
of a viral illness.
The baby was transferred to the neonatal nursery for further 
management. Clinical examination revealed symmetrical growth 
restriction, leukocoria of the left eye (later confirmed as a cataract), 
and a systolic murmur suggestive of a PDA.
Serum rubella IgM and urine rubella PCR were positive. A hearing 
screen before discharge was inconclusive, and the baby was discharged 
on day 4 with follow-up appointments at the cardiology, audiology, 
ophthalmology and neurodevelopmental clinics. The mother was 
referred to the social worker.
Discussion
Rubella was first recognised as a teratogen in 1941 when Gregg, an 
Australian ophthalmologist, associated intra-uterine infection with 
the development of cataracts and other defects.3 Classically CRS 
leads to the triad of deafness (80%), congenital cardiac disease (50 
- 70%, most commonly PDA or pulmonary stenosis) and cataracts 
(30%), but many other defects involving almost every organ have 
been described4 (Fig. 1).
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The risk is highest if the mother is infected in 
the first trimester of her pregnancy. Infection 
during this time carries a risk of CRS that 
can be as high as 90%, although spontaneous 
miscarriage is common.5-7 Sensorineural 
deafness can occur with infection right 
up to the 19th week of gestation and may 
only become evident later in childhood.8 
More severe complications include acute 
meningo-encephalitis (10 - 20%) and late-
onset progressive panencephalitis. The 
risk of intellectual disability, behavioural 
problems and autism are all increased in 
children with CRS. Studies have shown 
that affected adults also have an increased 
risk of developing endocrinopathies such 
as diabetes mellitus and thyroid problems.4 
Although CRS is a disease with a variable 
spectrum of clinical presentation and 
outcome, many patients require lifelong 
care. In the USA the lifetime cost of treating 
a patient with CRS is estimated to be more 
than $200 000.9
Congenital rubella is not a notifiable 
disease in South Africa, but it is estimated 
that about 660 cases of CRS occur in this 
country every year. The global incidence is in 
the region of 100 000 cases annually, mostly 
in developing countries.1,10,11 Epidemics 
usually occur every 4 - 7 years, but as there 
are no surveillance programmes in place, 
these outbreaks can occur without clinical 
recognition.12
Although screening for rubella antibodies 
in pregnancy is widespread in the private 
healthcare sector, no routine antenatal 
seroprevalence screening takes place in the 
public sector. However, a study by Corcoran 
and Hardie in the Western Cape found that 
95.3% of women in the 15 - 24-year age 
group, 97.5% in the 25 - 34-year age group 
and 98% in the 35 - 45-year age group were 
immune to rubella.13 Interestingly, Schoub 
et al. demonstrated a susceptibility gap 
(rubella IgG-negative) for women 12 - 49 
years of age in the private sector that was 
significantly greater than that in the public 
sector (10.7% v. 5.4%). This can probably 
be attributed to better socio-economic 
circumstances, less overcrowding, and partial 
immunisation of the population.1
In the affected infant, rubella can be 
confirmed by isolating virus from a 
nasopharyngeal swab, or PCR can be done 
on body fluids – urine is the easiest to collect. 
Infected infants can shed virus for up to 6 - 
12 months after birth, and occasionally for 
longer. Rubella-specific IgM can usually be 
detected in the first 6 months, and with the 
clinical picture of CRS is highly suggestive 
of prenatal infection. Rubella-specific IgG 
beyond 6 months can be detected in 95% of 
infants with CRS but may also be caused by 
postnatal infection or passively transferred 
maternal antibodies. This is what makes 
retrospective diagnosis of CRS in an older 
infant or child more difficult.8,14,15
Currently no definitive treatment for 
CRS exists and there is no role for passive 
immunisation with immune globulin after 
maternal exposure. Termination of pregnancy 
in confirmed cases of first-trimester 
infection should be discussed with parents 
after appropriate counselling, preferably by 
a specialist in congenital infectious diseases. 
Once a baby with CRS is born, isolation 
precautions should be instituted and these 
children should be considered infectious 
for the first year of life. Susceptible female 
healthcare workers or visitors should be 
informed of the potential risk of exposure. 
The use of chemotherapeutic agents such as 
amantadine, interferon and isoprinosine has 
shown no benefit.4
CRS is a chronic disease, and these children 
need to be followed up to detect progression 
and the emergence of new problems. A 
multidisciplinary team approach is required, 
involving medical, surgical, educational and 
rehabilitative management.
Vaccination
As rubella is typically a mild disease, the 
primary purpose of rubella vaccination is 
to prevent congenital rubella infection. 
The current vaccine is a live attenuated 
vaccine and contains the RA27/3 strain. 
It is safe, cheap and effective and can be 
administered either as a monovalent vaccine, 
or in combination with the measles (MR) 
or measles and mumps (MMR) vaccines.11 
Vaccine-induced protection is generally 
assumed to be lifelong and studies indicate 
that over 90% of vaccinees are protected for 
at least 15 years.16
Rubella vaccine is highly affordable, with the 
cost between $0.31 and $1.37 depending on 
the formulation.17 Owing to the high cost 
of treating infected individuals, cost-benefit 
analyses of vaccination in both developed and 
developing countries have shown ratios >1.9
However, rubella vaccination does not 
currently form part of the EPI in South 
Africa, although parents can have their 
children immunised in the private sector 
as part of the MMR vaccine, which can be 
given at 15 months, with a booster at age 5 
years.
In 2000 the World Health Organization 
(WHO) published its first rubella 
vaccination position paper to guide the 
introduction of rubella-containing vaccine 
(RCV) in national childhood immunisation 
schedules. From 1996 to 2009, the number 
of countries that introduced RCV into their 
national routine immunisation programmes 
increased by 57%. Many developing 
countries in South America, North 
Africa and parts of Asia now have rubella 
vaccination as part of their schedules.17 
However, RCV is not recommended for 
inclusion in the EPI of developing countries 
when sustained high immunisation coverage 
cannot be maintained, as this could increase 
the susceptibility of adult women by slowing, 
but not interrupting, rubella transmission 
and thereby theoretically actually increase 
the number of congenital rubella cases.16,18-20 
The WHO recommends first-dose measles-
containing vaccine coverage (MCV1) of 
>80% before RCV is introduced.11 In South 
Africa, all but 8 districts currently meet 
this criterion for the first dose of measles 
Fig. 1. Common clinical manifestations of congenital rubella syndrome.
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vaccine.21,22 The Department of Health is once again engaging in the 
WHO’s ‘Reaching Every District’ (RED) strategy to ensure coverage 
across the whole country.23
The use of MMR in the private sector may be contributing to a 
population of susceptible young women.20,24 It is estimated that about 
100 000 children per year utilise private vaccination facilities, with 
60% of these receiving rubella vaccination. This is significant enough 
to create an immunity gap in this population.1,25
A combined immunisation strategy has been found to be the most 
effective method of eradicating CRS. The immunisation of all infants 
will only eradicate CRS in 30 - 40 years and that of all schoolgirls 
presumably in 10 - 20 years. Universal childhood vaccination alone 
is not the recommended vaccination strategy – not only is the lag 
phase unacceptably long, but there is a risk of increased CRS cases 
initially, as seen in Greece in 1993.14,20 Vaccination of young women 
will eradicate CRS immediately, but only if 100% are immunised.
As the median age of sexual debut in South Africa is 16 - 17 years, 
an option would be to introduce vaccination to prepubescent girls, 
preferably at primary school, as part of the school health services.26 
At present regular healthcare visits at primary school are not well 
established, but this may change with the planned introduction of 
the combined diphtheria and tetanus vaccine (and potentially the 
human papillomavirus (HPV) vaccine) at age 12.27 High rates 
of female school attendance and good liaison between school and 
health authorities will be required.
Conclusion
In South Africa the exact burden of CRS is unknown. As CRS is 
potentially a preventable disease, although rare, every new case is not 
only a tragedy for the family but a failure of the health system.
Rubella vaccine is safe, effective and cheap with a favourable cost-
benefit ratio. There is potential to introduce the vaccine into the EPI. 
With careful planning it could be introduced at the same time as the 
HPV vaccine.
Although South Africa has many more pressing health and social 
issues, a marked reduction or even elimination of CRS cases is 
possible. It is to be hoped that in the future we will see even fewer 
cases of CRS in our units.
We are interested in finding out how many others have diagnosed 
cases of congenital rubella, and invite readers to send information to 
the corresponding author.
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